Total revenue impressively rose by 20% to $8.4 billion. However, earnings per share decreased by 46% to $1.38. Non-GAAP EPS showed a slight decrease of under 1% to $4.97. Amgen is a ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Non-GAAP earnings per share reached $5.58, surpassing the $5.11 expected by analysts. Revenue totaled $8.5 billion, in line with estimates and up from the previous year's $6.9 billion. Strategic ...